Pharmacokinetics of an extended-release theophylline product in cats.
J Am Vet Med Assoc, 2007/9/15;231(6):900-6.
Guenther-Yenke CL[1], McKiernan BC, Papich MG, Powell E
Affiliations
PMID: 17867974
Impact factor: 1.836
Abstract
objective: To evaluate the pharmacokinetics of a brand of extended-release theophylline tablets and capsules in healthy cats.
design: Randomized 3-way crossover study.
animals: 6 healthy cats.
procedures: A single dose of aminophylline (10 mg/kg [4.5 mg/lb], IV), a 100-mg extended-release theophylline tablet, or a 125-mg extended-release theophylline capsule was administered to all cats. Plasma samples were collected via preplaced central catheters throughout a 36-hour period. Plasma samples were frozen until analyzed by use of a fluorescence polarization monoclonal immunoassay.
results: All cats tolerated drug administration and plasma collection with no adverse effects. Peak concentrations were reached for both orally administered products between 8 and 12 hours after administration. Bioavailability was excellent. Plasma concentrations were within the human therapeutic concentration of 5 to 20 microg/mL.
conclusions and clinical relevance: Daily administration of the brand of theophylline tablets and capsules used in this study at 15 mg/kg (6.8 mg/lb) and 19 mg/kg (8.6 mg/lb), respectively, maintained plasma concentrations within the desired therapeutic range in healthy cats.
MeSH terms
Administration, Oral; Animals; Area Under Curve; Biological Availability; Bronchodilator Agents; Capsules; Cats; Cross-Over Studies; Delayed-Action Preparations; Injections, Intravenous; Tablets; Theophylline
More resources
EndNote: Download